Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

Report on how AI is redefining market landscape - The Global Gastrointestinal Diseases Therapeutics Market size is es ...

The need for antiemetic drugs, which help prevent or relieve nausea and vomiting, is growing for several reasons. A key factor is the rising incidence of conditions and treatments that cause these ...

In the future, around one third of the new products at Boehringer Ingelheim will come from oncology.” Newest technologies and laboratories allow scientists to faster achieve their goal to develop ...

Boehringer Ingelheim has opened a €60m ($66.8m) research building in Vienna, Austria, as the company looks to double down in the oncology therapeutics space. The building is named after Angelika ...

In patients with moderate to severe Crohn’s disease, guselkumab showed similar efficacy in both biologic-naive and ...